Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Exploring New Prognostic Biomarkers in Mantle Cell Lymphoma: The Best RNA Based Risk Score

Ruth Salim, Simon Husby, Christian Winther Eskelund, David W. Scott, Harald Holte, Arne Kolstad, Riikka Räty, Sara Ek, Mats Jerkeman, Christian H. Geisler, Lasse Sommer Kristensen, Mette Dahl, Kirsten Grønbæk

Blood (2022) 140 (Supplement 1): 9254–9256.

https://doi.org/10.1182/blood-2022-159472

Published: 2022

Journal Articles

Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial

Blood (2021) 138 (Supplement 1): 2639.

https://doi.org/10.1182/blood-2021-147790

Published: 2021

Journal Articles

High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial

Blood (2021) 138 (Supplement 1): 72.

https://doi.org/10.1182/blood-2021-147729

Published: 2021

Journal Articles

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Blood (2021) 138 (Supplement 1): 71.

https://doi.org/10.1182/blood-2021-146161

Published: 2021

Journal Articles

Pre-Treatment Health-Related Quality of Life Parameters May Have Prognostic Impact in Elderly Patients with Mantle Cell Lymphoma. the Nordic Lymphoma Group MCL4 (LENA-BERIT) Experience

Åsa Lindberg, III, Christian Winther Eskelund, Alexandra Albertsson-Lindblad, MD PhD, Arne Kolstad, MD PhD, Anna Laurell, MD PhD, Riikka Räty, MD PhD, Kirsten Grønbæk, Prof,MDDMSc, Christian H. Geisler, MD PhD, Mats Jerkeman, MD PhD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-133370

Published: 2020

Journal Articles

Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial

Mats Jerkeman, MD PhD, Martin Hutchings, MD PhD, Riikka Räty, MD PhD, Karin Fahl Wader, MD PhD, Anna Laurell, MD PhD, Jacob H. Christensen, MD, Hanne Kuitunen, MD, Christian Winther Eskelund, MD PhD, Kirsten Groenbaek, MD DMSc, Carsten Utoft Niemann, MD PhD, Christian H. Geisler, MD PhD, Arne Kolstad, MD PhD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-133298

Published: 2020

Journal Articles

Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL

Christian Winther Eskelund, Simon Husby, Francesco Favero, Tobias Wirenfeldt Klausen, Francisco German Rodriguez-Gonzalez, Arne Kolstad, Lone Bredo Pedersen, Riikka Katariina Räty, Christian H. Geisler, Mats Jerkeman, Joachim Weischenfeldt, Kirsten Grønbæk

Blood (2020) 135 (22): 2000–2004.

https://doi.org/10.1182/blood.2019003539

Published: 2020

Includes: Supplemental data

Journal Articles

A Circular RNA Molecule, circRAB11FIP1, Is Associated with TP53 Mutations and Is of Potential Prognostic and Functional Significance in Mantle Cell Lymphoma: Data from the Nordic MCL2 and MCL3 Studies

Mette Dahl, MD, Simon Husby, MD, Christian Winther Eskelund, MD, Christophe Côme, PhD, Sara Ek, PhD Professor, Arne Kolstad, MD PhD, Riikka Räty, PhD Associate professor, Mats Jerkeman, MD Professor, Christian H. Geisler, MD PhD, Lasse Sommer Kristensen, PhD Assistant professor, Kirsten Grønbæk, Professor, MD DMSc

Blood (2019) 134 (Supplement_1): 1495.

https://doi.org/10.1182/blood-2019-123989

Published: 2019

Journal Articles

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

Blood (2018) 131 (21): 2357–2366.

https://doi.org/10.1182/blood-2017-12-820910

Published: 2018

Includes: Supplemental data

Journal Articles

Patients with Chronic Lymphocytic Leukemia Belonging to the B-Cell Receptor Stereotypy Subset #2 Have Long Progression Free Survival after Chemo- or Chemoimmunotherapy in the HOVON68 Trial

Fie Juhl Vojdeman, MD, Lone Bredo Pedersen, Doreen Te Raa, MD PhD, Vesa Juvonen, PhD, Yvette Norden, Geir Erland Tjønnfjord, MD DMsc, Eva Kimby, Maija Itälä-Remes, MD PhD, Anton W Langerak, Ludo M. Evers, Thorsten Zenz, MD, Marinus H.J. Van Oers, MD PhD, Christian H. Geisler, MD PhD, Arnon P. Kater, MD, Carsten Utoft Niemann, MD PhD

Blood (2017) 130 (Supplement 1): 4312.

https://doi.org/10.1182/blood.V130.Suppl_1.4312.4312

Published: 2017

Journal Articles

Rituximab Maintenance after First-Line Immunochemotherapy in Mantle Cell Lymphoma: Long-Term Follow-up of the Randomized European MCL Elderly Trial

Blood (2017) 130 (Supplement 1): 153.

https://doi.org/10.1182/blood.V130.Suppl_1.153.153

Published: 2017

Journal Articles

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

Christian W. Eskelund, Christina Dahl, Jakob W. Hansen, Maj Westman, Arne Kolstad, Lone B. Pedersen, Carmen P. Montano-Almendras, Simon Husby, Catja Freiburghaus, Sara Ek, Anja Pedersen, Carsten Niemann, Riikka Räty, Peter Brown, Christian H. Geisler, Mette K. Andersen, Per Guldberg, Mats Jerkeman, Kirsten Grønbæk

Blood (2017) 130 (17): 1903–1910.

https://doi.org/10.1182/blood-2017-04-779736

Published: 2017

Includes: Supplemental data

Journal Articles

Resistance to Cytarabine in Mantle Cell Lymphoma Is Mediated By Down-Regulation of Deoxycytidine Kinase at the Protein Level

Catja Freiburghaus, PhD, Venera Kuci Emruli, PhD, Angelica Johansson, Roger Olsson, PhD, Fredrik Ek, PhD, Christian H Geisler, Mats Jerkeman, Sara Ek, PhD

Blood (2016) 128 (22): 1769.

https://doi.org/10.1182/blood.V128.22.1769.1769

Published: 2016

Journal Articles

Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: First Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial

Mats Jerkeman, Martin Hutchings, Riikka Räty, Karin Fahl Wader, Anna Laurell, Hanne Kuitunen, Helle Toldbod, Lone Bredo Pedersen, Christian Winther Eskelund, Kirsten Grønbæk, Carsten Utoft Niemann, Christian H Geisler, Arne Kolstad

Blood (2016) 128 (22): 148.

https://doi.org/10.1182/blood.V128.22.148.148

Published: 2016

Journal Articles

Molecular Monitoring and Tailored Strategy with Pre-Emptive Rituximab Treatment for Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-up of 8.5 Years

Arne Kolstad, MD PhD, Lone B Pedersen, Christian Winther Eskelund, Simon Husby, MD, Kirsten Grønbæk, Mats Jerkeman, Anna Laurell, Riikka Räty, Erkki Elonen, MD PhD, Niels S. Andersen, MD PhD, Peter de Nully Brown, MD PhD, Christian H Geisler

Blood (2016) 128 (22): 146.

https://doi.org/10.1182/blood.V128.22.146.146

Published: 2016

Journal Articles

Targeted Sequencing of Diagnostic Samples Correlated to Clinical Outcome: Data from the Nordic Mantle Cell Lymphoma (MCL2 and MCL3) Studies with Long-Term Follow-up

Christian Winther Eskelund, Jakob W Hansen, Maj Karoline Westman, MSc, Catja Freiburghaus, PhD, Sara Ek, PhD, Lone B Pedersen, Mette K Andersen, Riikka Räty, Arne Kolstad, Mats Jerkeman, Peter de Nully Brown, MD PhD, Christian H Geisler, Kirsten Groenbaek

Blood (2016) 128 (22): 1095.

https://doi.org/10.1182/blood.V128.22.1095.1095

Published: 2016

Journal Articles

Increased Risk of Second Hematological and Non-Hematological Malignancies in CLL Patients Treated with Chemotherapy As Compared to Untreated Patients and Matched Controls - Results from a Danish Population Based Study

Caspar Da Cunha-Bang, Klaus Rostgaard, Jacob Simonsen, Christian H Geisler, Henrik Hjalgrim, Henrik Frederiksen, MD PhD, Kirsten Grønbæk, Carsten Utoft Niemann

Blood (2016) 128 (22): 3219.

https://doi.org/10.1182/blood.V128.22.3219.3219

Published: 2016

Journal Articles

Improved Survival for Patients with CLL in the Era of Combination Chemoimmunotherapy - a Danish Population Based Study

Caspar da Cunha-Bang, Jacob Simonsen, Klaus Rostgaard, Christian H Geisler, Henrik Hjalgrim, Carsten Niemann

Blood (2015) 126 (23): 1740.

https://doi.org/10.1182/blood.V126.23.1740.1740

Published: 2015

Journal Articles

miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator

Blood (2015) 125 (17): 2669–2677.

https://doi.org/10.1182/blood-2014-06-584193

Published: 2015

Includes: Supplemental data

Journal Articles

Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations

Panagiotis Baliakas, Andreas Agathangelidis, Anastasia Hadzidimitriou, Lesley-Ann Sutton, Eva Minga, Athina Tsanousa, Lydia Scarfò, Zadie Davis, Xiao-Jie Yan, Tait Shanafelt, Karla Plevova, Yorick Sandberg, Fie Juhl Vojdeman, Myriam Boudjogra, Tatiana Tzenou, Maria Chatzouli, Charles C. Chu, Silvio Veronese, Anne Gardiner, Larry Mansouri, Karin E. Smedby, Lone Bredo Pedersen, Denis Moreno, Kirsten Van Lom, Véronique Giudicelli, Hana Skuhrova Francova, Florence Nguyen-Khac, Panagiotis Panagiotidis, Gunnar Juliusson, Lefteris Angelis, Achilles Anagnostopoulos, Marie-Paule Lefranc, Monica Facco, Livio Trentin, Mark Catherwood, Marco Montillo, Christian H. Geisler, Anton W. Langerak, Sarka Pospisilova, Nicholas Chiorazzi, David Oscier, Diane F. Jelinek, Nikos Darzentas, Chrysoula Belessi, Frederic Davi, Paolo Ghia, Richard Rosenquist, Kostas Stamatopoulos

Blood (2015) 125 (5): 856–859.

https://doi.org/10.1182/blood-2014-09-600874

Published: 2015

Includes: Supplemental data

NARROW

Exploring New Prognostic Biomarkers in Mantle Cell Lymphoma: The Best RNA Based Risk Score

Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial

High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Pre-Treatment Health-Related Quality of Life Parameters May Have Prognostic Impact in Elderly Patients with Mantle Cell Lymphoma. the Nordic Lymphoma Group MCL4 (LENA-BERIT) Experience

Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial

Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL

A Circular RNA Molecule, circRAB11FIP1, Is Associated with TP53 Mutations and Is of Potential Prognostic and Functional Significance in Mantle Cell Lymphoma: Data from the Nordic MCL2 and MCL3 Studies

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

Patients with Chronic Lymphocytic Leukemia Belonging to the B-Cell Receptor Stereotypy Subset #2 Have Long Progression Free Survival after Chemo- or Chemoimmunotherapy in the HOVON68 Trial

Rituximab Maintenance after First-Line Immunochemotherapy in Mantle Cell Lymphoma: Long-Term Follow-up of the Randomized European MCL Elderly Trial

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

Resistance to Cytarabine in Mantle Cell Lymphoma Is Mediated By Down-Regulation of Deoxycytidine Kinase at the Protein Level

Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: First Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial

Molecular Monitoring and Tailored Strategy with Pre-Emptive Rituximab Treatment for Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-up of 8.5 Years

Targeted Sequencing of Diagnostic Samples Correlated to Clinical Outcome: Data from the Nordic Mantle Cell Lymphoma (MCL2 and MCL3) Studies with Long-Term Follow-up

Increased Risk of Second Hematological and Non-Hematological Malignancies in CLL Patients Treated with Chemotherapy As Compared to Untreated Patients and Matched Controls - Results from a Danish Population Based Study

Improved Survival for Patients with CLL in the Era of Combination Chemoimmunotherapy - a Danish Population Based Study

miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator

Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only